Government prohibits distribution, sale of Buclizine as ‘appetite stimulant’

New Delhi: The Union Health Ministry has prohibited the distribution and sale of anti-histamine drug Buclizine as an appetite stimulant “in public interest” under the Drugs and Cosmetics Act. The drug will, however, be allowed to be marketed for “symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness.”

According to a notification from the ministry, the Central government regulates the manufacture, sale or distribution of Buclizine and its formulations for use in human beings, subject to conditions that the manufacturer “shall label the container of Buclizine and its formulation and also mention in conspicuous manner on the package insert and promotional literature of Buclizine and its formulation with the words ‘Not to be used as appetite stimulant'”.

It was brought to the notice of the government that the use of the drug Buclizine as appetite stimulant for human use was not rational, the notification stated.

The matter was examined by a subject expert committee constituted by the government.

The committee stated that no clinical trial study report on human beings to justify the use of Buclizine as an appetite stimulant has been produced by the manufacturers and hence, the committee had not recommended the continued marketing of the drug as an appetite stimulant.

The Drugs Technical Advisory Board had also recommended prohibiting the manufacture, sale and distribution of Buclizine for the indication “as appetite stimulant” in public interest and continuing the marketing for the indications “symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness”.

“After examination of the recommendations of the Subject Expert Committee and Drugs Technical Advisory Board, the Central Government is satisfied that the use of said drug Buclizine do not have any therapeutic value claimed for as an appetite stimulant and is likely to involve risk to human beings,” the notification said.

  • Related Posts

    Unapproved drops for dry eyes pose risks: Govt

    NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Govt highlights multi-layer framework to curb misleading advertisements

    Govt highlights multi-layer framework to curb misleading advertisements

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Study finds rising resistance to a last-resort antibiotic in Africa

    Study finds rising resistance to a last-resort antibiotic in Africa